Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эбботт Гмбх Унд Ко. Кг, Эбботт ЛэборетризfiledCriticalЭбботт Гмбх Унд Ко. Кг
Publication of UA99343C2publicationCriticalpatent/UA99343C2/en
Preparation Of Compounds By Using Micro-Organisms
(AREA)
Abstract
The invention relates to monoclonal antibodies, which have the ability for detecting RGM A and for inhibiting RGM A activity, for example in a human suffering from a disorder including but not limited to multiple sclerosis, mammalian brain trauma, spinal cord injury, stroke, neurodegenerative diseases, and schizophrenia.
UAA201011557A2008-02-292009-02-27Monoclonal antibodies against the rgm a protein and uses thereof
UA99343C2
(en)
Structure-guided identification of binding interactions of human laminin receptor precursor with laminin and identification of compounds that affect binding